CA
SVA

Clearstead Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Clearstead Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
500
– – ﹤0.01% 2905
2025
Q4 		$0 Hold
500
– – ﹤0.01% 3333
2025
Q3 		$0 Hold
500
– – ﹤0.01% 3289
2025
Q2 		$0 Buy
+500
New – ﹤0.01% 2906
2024
Q3 		– Sell
-500
Closed – – 2141
2024
Q2 		$0 Hold
500
– – ﹤0.01% 2087
2024
Q1 		$0 Buy
+500
New – ﹤0.01% 1660
2023
Q4 		– Sell
-1,000
Closed – – 1672
2023
Q3 		$0 Buy
1,000
+500
+100% – ﹤0.01% 1589
2023
Q2 		$0 Buy
+500
New – ﹤0.01% 1463
2022
Q4 		– Sell
-500
Closed – – 1416
2022
Q3 		$0 Hold
500
– – ﹤0.01% 1410
2022
Q2 		$0 Buy
+500
New – ﹤0.01% 1515
2022
Q1 		– Sell
-500
Closed – – 1491
2021
Q4 		$0 Buy
+500
New – ﹤0.01% 1491

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Clearstead Advisors's SVA Position: Q1 2026 in Review

Clearstead Advisors held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 500 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

Clearstead Advisors first reported a position in SVA in Q4 2021 and has held it in 11 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Clearstead Advisors held 500 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
  • Clearstead Advisors left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #2905 holding.
  • Clearstead Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2021 and has held it in 11 quarters since.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.